Stock 1734 SINPHAR PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sinphar Pharmaceutical Co.,Ltd.

Equities

1734

TW0001734002

Pharmaceuticals

End-of-day quote Taiwan S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
36.5 TWD +0.83% Intraday chart for Sinphar Pharmaceutical Co.,Ltd. +0.41% +7.51%
05-15 Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-26 Sinphar Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,237 3,254 5,191 4,847 5,560 5,694
Enterprise Value (EV) 1 4,025 4,310 6,154 5,737 6,229 6,558
P/E ratio 386 x 243 x -182 x -127 x 24.8 x 15.2 x
Yield 0.52% 1.03% 0.65% 0.69% 3.02% 2.95%
Capitalization / Revenue 1.46 x 1.36 x 2.17 x 1.99 x 1.95 x 1.92 x
EV / Revenue 1.82 x 1.8 x 2.58 x 2.36 x 2.18 x 2.21 x
EV / EBITDA 41.2 x 54.9 x 54.6 x 89.7 x 13.9 x 12.7 x
EV / FCF -35.9 x -21.6 x 69.7 x 87 x 30.1 x -52.1 x
FCF Yield -2.78% -4.62% 1.43% 1.15% 3.32% -1.92%
Price to Book 1.11 x 1.17 x 1.89 x 1.78 x 1.9 x 1.84 x
Nbr of stocks (in thousands) 167,722 167,722 167,722 167,722 167,722 167,722
Reference price 2 19.30 19.40 30.95 28.90 33.15 33.95
Announcement Date 01/04/19 27/03/20 30/03/21 31/03/22 30/03/23 26/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,216 2,395 2,388 2,434 2,857 2,963
EBITDA 1 97.77 78.48 112.7 63.93 446.7 518.1
EBIT 1 -119.3 -147 -122.2 -182.8 198.6 288.7
Operating Margin -5.38% -6.14% -5.12% -7.51% 6.95% 9.75%
Earnings before Tax (EBT) 1 -87.68 -86.71 -117.8 -184.5 245 305.7
Net income 1 8.785 13.96 -28.51 -38.14 224.6 375.2
Net margin 0.4% 0.58% -1.19% -1.57% 7.86% 12.66%
EPS 2 0.0500 0.0800 -0.1700 -0.2274 1.339 2.230
Free Cash Flow 1 -112 -199.1 88.23 65.95 206.6 -125.8
FCF margin -5.05% -8.32% 3.69% 2.71% 7.23% -4.25%
FCF Conversion (EBITDA) - - 78.31% 103.16% 46.25% -
FCF Conversion (Net income) - - - - 91.97% -
Dividend per Share 2 0.1000 0.2000 0.2000 0.2000 1.000 1.000
Announcement Date 01/04/19 27/03/20 30/03/21 31/03/22 30/03/23 26/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 788 1,056 963 889 669 864
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 8.061 x 13.46 x 8.544 x 13.91 x 1.497 x 1.667 x
Free Cash Flow 1 -112 -199 88.2 65.9 207 -126
ROE (net income / shareholders' equity) -3.49% -4.47% -5.44% -6.59% 5.22% 10.8%
ROA (Net income/ Total Assets) -1.25% -1.56% -1.27% -1.85% 2% 2.9%
Assets 1 -702.4 -896.4 2,248 2,061 11,225 12,928
Book Value Per Share 2 17.40 16.60 16.40 16.20 17.50 18.50
Cash Flow per Share 2 5.710 5.010 6.820 7.120 7.380 6.410
Capex 1 249 168 144 146 141 296
Capex / Sales 11.24% 7% 6.03% 6.01% 4.95% 9.97%
Announcement Date 01/04/19 27/03/20 30/03/21 31/03/22 30/03/23 26/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SINPHAR PHARMACEUTICAL CO.,LTD. Stock Sinphar Pharmaceutical Co.,Ltd.
+7.51% 188M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+15.91% 41.97B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.40% 22.34B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.48% 15.25B
CIPLA LIMITED Stock Cipla Limited
+16.12% 14B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.12% 12.06B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.58% 6.8B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.18% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1734 Stock
  4. Financials Sinphar Pharmaceutical Co.,Ltd.